Abstract
[...]this paper would add most required clarity on the utilization of Apomorphine in Indian subjects and their responses to therapies. Long-term utilization and experiences are planned via the setup of an academic registry and in due time will add various aspects of this therapy in Indian subjects. [...]the molecule was not available in the Indian market directly to the patients. [...]similar to the process wherein levodopa is used in atypical parkinsonism patients in whom clinical benefits are noted, Apomorphine can also be considered for clinical benefits if requisite indications are met (like rescue therapy, uncomfortable fluctuations, etc.).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Center for Parkinson's Disease and Movement Disorders Clinic; Department of Neurology, Institute of Neurosciences, Vikram Hospitals; Parkinson's Disease and Movement Disorders Clinic, Bengaluru, Karnataka
2 Department of Neurology, Institute of Neurosciences, Vikram Hospitals, Bengaluru, Karnataka